Profile data is unavailable for this security.
About the company
Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
- Revenue in EUR (TTM)28.63m
- Net income in EUR-8.61m
- Incorporated2000
- Employees91.00
- LocationBiofrontera AGHemmelrather Weg 201LEVERKUSEN 51377GermanyDEU
- Phone+49 214876320
- Fax+49 2 148763290
- Websitehttps://biofrontera.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2cureX AB | 13.32k | -2.65m | 663.94k | -- | -- | 0.5645 | -- | 49.86 | -1.75 | -1.75 | 0.0088 | 0.7777 | 0.0048 | -- | 0.0838 | -- | -95.89 | -38.21 | -108.66 | -43.48 | -6,889.68 | -22,153.06 | -19,883.23 | -38,685.30 | -- | -46.08 | -- | -- | 72.22 | -- | -3.52 | -- | -- | -- |
| Stayble Therapeutics AB | 0.00 | -2.04m | 679.98k | 3.00 | -- | 0.4794 | -- | -- | -0.9492 | -0.9492 | 0.00 | 0.5204 | 0.00 | -- | -- | 0.00 | -116.21 | -78.64 | -141.76 | -95.58 | -- | -- | -- | -- | -- | -- | 0.049 | -- | -- | -- | 3.22 | -- | -- | -- |
| Voyager Life PLC | 365.79k | -1.28m | 734.06k | 28.00 | -- | 0.9933 | -- | 2.01 | -0.0912 | -0.0912 | 0.0253 | 0.044 | 0.1897 | 1.58 | 3.85 | 11,214.29 | -66.51 | -- | -77.02 | -- | 41.72 | -- | -350.64 | -- | 2.83 | -69.50 | 0.4625 | -- | 59.55 | -- | -38.70 | -- | -- | -- |
| Ovoca Bio PLC | 0.00 | -2.33m | 782.93k | 5.00 | -- | 0.1548 | -- | -- | -0.0246 | -0.0246 | 0.00 | 0.0532 | 0.00 | -- | -- | 0.00 | -27.00 | -17.82 | -32.86 | -19.39 | -- | -- | -- | -- | 4.68 | -48.64 | 0.00 | -- | -- | -- | -6.96 | -- | -- | -- |
| Carbiotix AB (publ) | 125.91k | -1.16m | 870.24k | 10.00 | -- | 0.1473 | -- | 6.91 | -0.302 | -0.302 | 0.0324 | 0.3817 | 0.0586 | -- | 2.36 | 146,552.00 | -53.88 | -49.38 | -64.85 | -55.50 | 235.45 | 574.69 | -919.76 | -1,828.86 | -- | -76.28 | 0.1384 | -- | 259.56 | -12.04 | -10.02 | -- | 13.64 | -- |
| Oxurion NV | 263.00k | -18.97m | 901.48k | 20.00 | -- | -- | -- | 3.43 | -0.023 | -0.023 | 0.0002 | -0.0038 | 0.0284 | 63.60 | 0.1253 | 13,150.00 | -204.59 | -84.30 | -- | -118.70 | 39.54 | 48.90 | -7,212.55 | -2,008.99 | 0.1398 | -1.75 | -- | -- | -55.80 | -45.20 | 40.13 | -- | -65.17 | -- |
| Amniotics AB (publ) | 0.00 | -2.65m | 915.79k | 6.00 | -- | 0.6803 | -- | -- | -0.0374 | -0.0374 | 0.00 | 0.0057 | 0.00 | -- | -- | 0.00 | -112.25 | -101.09 | -362.71 | -149.92 | -- | -- | -- | -- | 1.12 | -16.17 | -- | -- | -- | -- | 35.75 | -- | -- | -- |
| Lidds AB | 0.00 | -3.45m | 955.55k | 2.00 | -- | 0.8002 | -- | -- | -0.7253 | -0.7253 | 0.00 | 0.2037 | 0.00 | -- | -- | 0.00 | -184.53 | -46.33 | -274.92 | -51.61 | -- | -- | -- | -3,076.68 | -- | -- | -- | -- | -100.00 | -- | -9.08 | -- | -- | -- |
| Biofrontera AG | 28.63m | -8.61m | 1.01m | 91.00 | -- | 1.53 | -- | 0.0355 | -0.1383 | -0.1383 | 0.4748 | 0.2177 | 1.08 | 1.04 | 31.02 | 353,444.40 | -32.43 | -15.40 | -53.10 | -19.25 | 80.07 | 84.31 | -30.06 | -28.83 | 1.10 | 0.1264 | 0.0813 | -- | -10.59 | 16.44 | -215.26 | -- | 19.83 | -- |
| Eurocine Vaccines AB | 430.00 | -1.29m | 1.09m | 3.00 | -- | -- | -- | 2,533.20 | -0.1472 | -0.1472 | 0.00005 | -0.0018 | 0.0007 | -- | 0.002 | -- | -199.76 | -83.17 | -323.19 | -97.89 | -199,780.00 | -- | -301,180.00 | -- | -- | -- | -- | -- | -- | -- | 8.95 | -- | -- | -- |
| Aptahem AB | 2.75k | -954.79k | 1.16m | -- | -- | 0.1324 | -- | 423.25 | -0.0497 | -0.0497 | 0.0001 | 0.2266 | 0.0005 | -- | 0.0738 | -- | -16.76 | -39.26 | -19.47 | -44.19 | 4,623.59 | -- | -34,727.72 | -- | -- | -10.17 | 0.0847 | -- | -- | -- | -25.36 | -- | -- | -- |
| Rapid Nutrition PLC | 1.80m | -1.43m | 1.24m | 9.00 | 53.81 | 743.95 | -- | 0.6926 | 0.0017 | 0.0017 | 0.0034 | 0.0001 | 1.84 | 3.90 | 3.05 | 199,527.30 | -146.98 | -- | -1,011.07 | -- | 71.47 | -- | -79.74 | -- | 1.07 | -- | 0.7674 | -- | -1.50 | -- | -1,090.33 | -- | -- | -- |
| AegirBio AB | 8.51k | -31.53m | 1.30m | 1.00 | -- | 1.70 | -- | 153.14 | -24.31 | -24.31 | 0.0047 | 0.2895 | 0.0004 | 2.00 | 0.0207 | -- | -163.02 | -- | -171.79 | -- | -24,398.99 | -- | -370,710.10 | -- | 2.53 | -27.27 | 0.8209 | -- | -87.16 | -- | -292.98 | -- | -- | -- |
